Finance

Lists
Q3 2026 earnings • released • EPS miss -4.46% • Revenue beat +∞%
See results
INBX:NASDAQ
Inhibrx Biosciences Inc
$83.30
-5.07%
(-4.44) 1D
$79.56
-4.49% (-3.74)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INBX...
Open
$87.91
High
$87.91
Low
$80.68
Mkt. cap
1.23B
Avg. vol.
267.46K
Volume
245.90K
52-wk high
$155.29
52-wk low
$57.30
EPS
-$8.88
Shares outstanding
14.72M
No. of employees
110
Open
$87.91
High
$87.91
Low
$80.68
Mkt. cap
1.23B
Avg. vol.
267.46K
Volume
245.90K
52-wk high
$155.29
52-wk low
$57.30
EPS
-$8.88
Shares outstanding
14.72M
No. of employees
110
News stories
From web sources and news partners
About Inhibrx Biosciences Inc
CEO-
Employees110
Founded2024
HeadquartersLa Jolla, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteinhibrx.com
Analyst ratings
Based on 3 analysts giving stock ratings to INBX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INBX in the last 3 months.
Highest
Current $83.30
$325.00 (+290.16%)
Average
$266.67 (+220.13%)
Lowest
$230.00 (+176.11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Dara Azar
Stifel Nicolaus
Buy
Maintained
$325.00
+290.2%
10/29/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$245.00
+194.1%
09/09/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
$230.00
+176.1%
09/08/2026
Unknown Analyst
Stifel Nicolaus
Buy
Initiated
$150.00
+80.1%
04/08/2026
Last report
Nov 13, 2026
Fiscal period
Q3 2026
-$2.46 / -$2.36
-4.46%miss
Revenue / Est. (USD)
2.00M / 0.00
+∞%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
28.54M
25.35M
25.22M
23.90M
Cost of revenue
28.54M
25.35M
25.22M
23.90M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.28M
5.57M
5.71M
8.25M
Operating expense
5.28M
5.57M
5.71M
8.25M
Total operating expenses
33.81M
30.92M
30.93M
32.15M
Operating income
-33.81M
-30.92M
-30.93M
-32.15M
Other non operating income
-46.00K
-39.00K
-12.00K
-68.00K
EBT including unusual items
-35.26M
-32.83M
-33.44M
-36.65M
EBT excluding unusual items
-35.26M
-32.83M
-33.44M
-36.65M
Income tax expense
-
-
-
3.00K
Effective tax rate
-
-
-
-0.01%
Other operating expenses
-
-
-
-
Net income
-35.26M
-32.83M
-33.44M
-36.65M
Net profit margin
-
-
-
-
Earnings per share
-2.28
-2.11
-2.15
-2.34
Interest and investment income
1.78M
1.31M
1.01M
1.26M
Interest expense
-3.18M
-3.18M
-3.51M
-5.69M
Net interest expenses
-1.40M
-1.87M
-2.50M
-4.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.23M
-30.36M
-30.39M
-31.63M
Gain or loss from assets sale
3.00K
9.00K
-
14.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps